Recurrent Nasopharynx Carcinoma Clinical Trial
Official title:
High Dose Conditioning With Ifosfamide, Carboplatin, and Etoposide With Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma
Verified date | May 2019 |
Source | University of Florida |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a pilot study to evaluate the response rates for patients undergoing high dose conditioning chemotherapy using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of recurrent Nasopharyngeal Cancer (NPC) in children, adolescents, and young adults.
Status | Terminated |
Enrollment | 1 |
Est. completion date | May 9, 2017 |
Est. primary completion date | May 9, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 30 Years |
Eligibility |
Inclusion Criteria: - Imaging and tissue diagnosis of recurrent or progressive nasopharyngeal carcinoma - Documentation of previous treatment including conventional chemotherapy and/or radiation therapy as clinically appropriate - Ages 2 to 30 years of age - Negative serum pregnancy test if applicable - Calculated creatinine clearance of greater than 60 mL/minute, serum creatinine of less than 12o micromoles/L, total bilirubin less than 2 mg/dL and aspartate aminotransferase (AST) must be less than twice the upper limit of normal Exclusion Criteria: - Unsuitable candidate for autologous transplantation due to comorbidities or intractable psychosocial issues - Pregnancy - Breast-feeding women |
Country | Name | City | State |
---|---|---|---|
United States | UF Health Shands Hospital | Gainesville | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Florida |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate the Tumor Response | To evaluate the response rates for patients undergoing high dose conditioning using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of recurrent NPC in children, adolescents, and young adults. | 12 months after completion of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02538510 -
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03074513 -
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
|
Phase 2 | |
Terminated |
NCT02706691 -
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT02339558 -
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
|
Phase 2 |